Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a potato starch supplement help stem cell transplant recovery?

NCT ID NCT05135351

Disease control Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests whether a prebiotic supplement called resistant starch can improve gut microbiome diversity in people with multiple myeloma or lymphoma after an autologous stem cell transplant. Thirty participants will take either the prebiotic or a placebo for about 10 days before and after their stem cell infusion. The main goal is to see if this approach is feasible and whether it affects gut bacteria diversity at the time of engraftment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Resistant starch (a prebiotic supplement)
What this could lead to
If it works, this could point toward a simple dietary supplement to improve gut health and possibly outcomes after stem cell transplant.
What could go wrong
This is a very small pilot study (30 people) testing feasibility, not effectiveness. The supplement may not change gut diversity or improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing to provide informed consent 2. Willing to comply with all study procedures and be available for the duration of the study 3. Has pathologically confirmed multiple myeloma, Non-Hodgkin lymphoma (DLBCL, mantle cell lymphoma, follicular lymphoma, or peripheral T-cell lymphoma), or Hodgkin lymphoma as determined on medical record review per standard of care transplant procedures (no tissue required for study) 4. Meeting a standard-of-care indication for autologous stem cell transplantation for the above diseases as determined by the investigator 5. Adult Individuals (male or female) at least 19 years of age 6. Meeting indications and recommended for first autologous stem cell transplantation by investigator Exclusion Criteria: 1. History of bariatric surgery (i.e. gastric banding, sleeve gastrectomy, Roux-en-Y bypass), chronic gastrointestinal disease including chronic diarrheal illness or inflammatory bowel disease 2. Previous intolerance to fiber supplementation 3. Allergy or intolerance to potato starch or maltodextrin 4. Subject unwilling to comply with stool sample collection 5. Not suitable for study participation due to other reasons at the discretion of the investigators Eligibility Criteria for CAR T-cell Therapy Cohort Inclusion Criteria: 1. Willing to provide informed consent 2. Willing to comply with all study procedures and be available for the duration of the study 3. Has pathologically confirmed lymphoma or multiple myeloma meeting a commercial indication for CAR-T cell therapy 4. Adult Individuals (male or female) at least 19 years of age 5. Meeting indications and recommended for CAR-T cell therapy by investigator Exclusion Criteria: 1. History of bariatric surgery (i.e. gastric banding, sleeve gastrectomy, Roux-en-Y bypass), chronic gastrointestinal disease including chronic diarrheal illness or inflammatory bowel disease, or other GI surgery risking diminished effect or tolerance to therapy as determined by investigator 2. Previous intolerance to fiber supplementation 3. Allergy or intolerance to resistant starch or maltodextrin 4. Subject unwilling to comply with stool sample collection 5. Not suitable for study participation due to other reasons at the discretion of the investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma lymphoma non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Unversity of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.